

World Journal of *Meta-Analysis*

World J Meta-Anal 2019 July 31; 7(7): 339-372



EDITORIAL

- 339 Asymptomatic bacteriuria among hospitalized diabetic patients: Should they be treated?
Ramos-Ramirez MJ, Surani S
- 343 Artificial intelligence for endoscopy
Imaeda H, Tsuzuki Y, Miyaguchi K, Ashitani K, Ohgo H, Nakamoto H

OPINION REVIEW

- 346 Phantom of the inflammasome in the gut: Cytomegalovirus
Arslan F, Vahaboglu H

SYSTEMATIC REVIEWS

- 350 Pediatric recurrent *Clostridium difficile* infections in immunocompetent children: Lessons learned from case reports of the first twelve consecutive patients
Chu A, Michail S

META-ANALYSIS

- 358 Effect of dl-3-n-butylphthalide on infarction volume in animal models of ischemic stroke: A meta-analysis
Luan D, Wu ZY, Zhang YX, Yuan LL, Xu Y, Chu ZH, Ma LS, Wang YP, Zhao SC

ABOUT COVER

Editorial Board of *World Journal of Meta-Analysis*, Edmundas Kadusevicius, PhD, Professor, Department of Clinical Pharmacology, Institute of Physiology and Pharmacology, Lithuanian University of Health Sciences, Kaunas LT-50009, Lithuania

AIMS AND SCOPE

The *World Journal of Meta-Analysis (WJMA)* is an online, open-access, single-blind peer-reviewed journal that is published by Baishideng Publishing Group. Accepting both solicited and unsolicited manuscripts, the *WJMA* mainly publishes high quality meta-analysis and systematic review articles to lead the development of various fields of clinical medicine. The type of articles published in the *WJMA* include the editorial, minireview, review, meta-analysis, meta-regression, systematic review, and evidence-based practice.

The primary aim of the *WJMA* is to provide scholars and readers from various fields of clinical medicine with a platform to publish high quality meta-analysis and systematic review articles and communicate their research findings online.

The *WJMA* mainly publishes research results and findings obtained through meta-analysis and systematic review in a wide range of areas, including medicine, pharmacy, etc.

INDEXING/ABSTRACTING

The *WJMA* is now abstracted and indexed in Emerging Sources Citation Index (Web of Science), China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database

RESPONSIBLE EDITORS FOR THIS ISSUE

Responsible Electronic Editor: *Ji-Hong Liu*
 Proofing Production Department Director: *Yun-Xiaojuan Wu*

NAME OF JOURNAL

World Journal of Meta-Analysis

ISSN

ISSN 2308-3840 (online)

LAUNCH DATE

May 26, 2013

FREQUENCY

Irregular

EDITORS-IN-CHIEF

Giuseppe Biondi-Zoccai

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/2308-3840/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director

PUBLICATION DATE

July 31, 2019

COPYRIGHT

© 2019 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Effect of dl-3-n-butylphthalide on infarction volume in animal models of ischemic stroke: A meta-analysis

Di Luan, Zheng-Yu Wu, Yuan-Xiang Zhang, Li-Li Yuan, Yang Xu, Zhao-Hu Chu, Ling-Song Ma, Ya-Ping Wang, Shou-Cai Zhao

ORCID number: Di Luan (0000-0002-8832-7555); Zheng-Yu Wu (0000-0002-0416-0760); Yuan-Xiang Zhang (0000-0002-0317-9435); Lili Yuan (0000-0002-5497-6338); Yang Xu (0000-0001-8778-3885); Zhao-Hu Chu (0000-0002-8103-5533); Ling-Song Ma (0000-0001-9035-0159); Ya-Ping Wang (0000-0002-1753-0863); Shou-Cai Zhao (0000-0001-8555-4835).

Author contributions: Luan D, Wu ZY, Zhang YX, Yuan LL, and Zhao SC conceived and designed the study; study searching was done by Luan D and Wu ZY. Further, studies screening and selection was done by Luan D and Wu ZY independently and disagreement was resolved by Zhao SC, Xu Y, Chu ZH, and Ma LS. Luan D and Wu ZY performed data extraction independently. Wang YP did analysis in supervision of Zhao SC. All authors were involved in interpretation of the results. The final draft of this manuscript was done by Luan D and read and approved by all the authors.

Supported by the National Natural Science Foundation of China, NO. 81701161.

Conflict-of-interest statement: The authors deny any conflict of interest.

PRISMA 2009 Checklist statement: The manuscript is designed as per PRISMA 2009 guideline and checklist is provided as supplementary file.

Open-Access: This article is an open-access article which was

Di Luan, Li-Li Yuan, Yang Xu, Zhao-Hu Chu, Ling-Song Ma, Ya-Ping Wang, Shou-Cai Zhao, Department of Neurology, Yijishan Hospital affiliated to Wannan Medical College, Wuhu 241000, Anhui Province, China

Zheng-Yu Wu, Yuan-Xiang Zhang, Department of Clinical Pharmacy, Yijishan Hospital affiliated to Wannan Medical College, Wuhu 241000, Anhui Province, China

Corresponding author: Shou-Cai Zhao, MD, Doctor, Professor, Teacher, Department of Neurology, Yijishan Hospital affiliated to Wannan Medical College, Wuhu 241000, Anhui Province, China. neurozsc@wnmc.edu.cn
Telephone: +86-18505539779

Abstract

BACKGROUND

Ischemic stroke is a frequently-occurring disease in the elderly and characterized by high morbidity and mortality. DL-3-n-butylphthalide (NBP), a synthetic compound based on natural celery seeds, has potential therapeutic effects on cerebral ischemia, brain trauma, memory impairment, and epilepsy.

AIM

To evaluate the effect of NBP on infarct volume in experimental ischemic stroke.

METHODS

Twenty one relevant literatures were included from the PubMed, EMBASE, Web of Science, Chinese National Knowledge Infrastructure, VIP information database, and Wanfang database, and data on the effect of dl-3-n-butylphthalide on infarction volume in the middle cerebral artery occlusion model were extracted. Statistical analysis was performed using standard mean difference with random effects model of Revman 5.3.

RESULTS

The data of meta-analysis of the 21 studies had suggested that NBP reduced the cerebral infarction volume of middle cerebral artery occlusion model animals compared to the control group significantly [SMD: -3.97, 95%CI: -4.71 to -3.23, $P < 0.01$; heterogeneity: $\chi^2 = 59.09$, $df = 20$ ($P < 0.01$); $I^2 = 66\%$].

CONCLUSION

NBP was effective in experimental ischemic stroke.

Key words: Butylphthalide; Animal model; Ischemic stroke; Meta-analysis

selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Received: May 10, 2019

Peer-review started: May 14, 2019

First decision: July 26, 2019

Revised: July 27, 2019

Accepted: July 29, 2019

Article in press: July 29, 2019

Published online: July 31, 2019

P-Reviewer: Tang Y

S-Editor: Wang JL

L-Editor: A

E-Editor: Wu YXJ



©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The systematic review of animal research is of great significance in drug development. This study reports for the first time a systematic review and meta-analysis of the effects of butylphthalide on the volume of cerebral infarction in experimental ischemic stroke.

Citation: Luan D, Wu ZY, Zhang YX, Yuan LL, Xu Y, Chu ZH, Ma LS, Wang YP, Zhao SC. Effect of dl-3-n-butylphthalide on infarction volume in animal models of ischemic stroke: A meta-analysis. *World J Meta-Anal* 2019; 7(7): 358-372

URL: <https://www.wjgnet.com/2308-3840/full/v7/i7/358.htm>

DOI: <https://dx.doi.org/10.13105/wjma.v7.i7.358>

INTRODUCTION

Ischemic stroke is a frequently-occurring disease in the elderly and characterized by high morbidity and mortality^[1,2]. The current treatment includes drug-based thrombolysis and interventional therapy in acute stage, however there were many inherent limitations of it^[3,4]. To date, more than 1000 clinical trials of potential neuroprotective drugs have been verified to be failures^[5].

DL-3-n-butylphthalide (NBP), a synthetic compound based on natural celery seeds, has potential therapeutic effects on cerebral ischemia, brain trauma, memory impairment, and epilepsy, of which the injectable formulations have been approved for the treatment of acute ischemic stroke in China^[6]. NBP protects the integrity of cerebrovascular structures^[7], promotes the formation of collateral circulation, accelerates the proliferation of neonatal capillary^[8,9], and increases the cerebral blood perfusion^[10]; by targeting mitochondria, it improves neuronal energy metabolism^[11], reduces oxidative stress damage and neuronal apoptosis^[12]. The systematic review of animal research is of great significance in drug development^[13]. To this end, we conducted a meta-analysis of preclinical studies to evaluate the efficacy and the mechanisms of NBP for experimental ischemic stroke.

MATERIALS AND METHODS

Literature search strategies

This meta-analysis was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement^[14]. All Chinese and English literatures before August 2018 on the effects of NBP for experimental ischemic stroke were searched in the six databases, which included PubMed, EMBASE, Web of Science, Wanfang database, VIP Chinese Journal Service Platform database and China National Knowledge Infrastructure database. Furthermore, to further confirm the relevant literature, we searched the list of references for potential publications. In the retrieval of the Web of Science, PubMed and EMBASE databases, only one keyword of "butylphthalide" was retrieved. In the searching of other databases, the following search strategy: "butylphthalide" AND "cerebral ischemia OR brain ischemia OR cerebral infarction OR brain infarction OR stroke OR cerebral ischemia/reperfusion OR cerebral I/R" were performed.

Inclusion and exclusion criteria

The inclusion criteria must be met the follows: (1) The experimental ischemic stroke model was established by the adoption of middle cerebral artery occlusion (MCAO); (2) The intervention group used NBP and the control group applied blank or non-functional solvent; and (3) The cerebral infarct volume was included in the study results and the unit of infarct volume was "%", and the calculation formula was (infarction volume / whole brain volume) × 100%. The exclusion criteria were followed: (1) The intervention group was not administered NBP or the intervention group was taken NBP with other medicines concomitantly; (2) The animal models was not adopt for proceeding to MCAO; (3) Without control group; (4) Repeating literature; and (5) The data were not available.

Literature screening and data extraction

By reading the title, abstract and full text according to the inclusion and exclusion criteria, the literature and extracted data were screened independently and cross-checked by the first author and the second author. When there was a disagreement, the point must be reached through the discussion panel which consisted of all authors, and the final conclusion was determined by the corresponding author.

Extracting the following data from the included literature: (1) The year of publication and the name of the first author; (2) The species, age, weight, gender, anesthesia methods, and model types of experimental animals (transient MCAO or permanent MCAO); (3) Therapeutic dose, route of administration, time of onset of treatment, and duration of treatment of the interventions; (4) The mean value and standard deviation of the cerebral infarction volume; and (5) The potential therapeutic mechanism of NBP for ischemic stroke.

Moreover, to study the multiple doses and multiple time points on effects of NBP, the final experimental data using the highest dose was extracted; If the volume of cerebral infarction cannot be obtained directly from the original text, the author of the literature is contacted by e-mail to get complete data, and if not, calculation was performed by using digital scale software.

Quality assessment

The risk of bias tool of the Systematic Review Centre for Laboratory animal Experimentation's was applied to assess the methodological quality of the included studies^[15]: (1) Baseline characteristics: The strain, gender, age, weight, anesthesia methods, name and anesthetic dose of the experimental animals were involved; (2) Allocation concealment: The experimental animals were grouped randomly; (3) Sequence generation: The generation of allocation sequence was random; (4) Random housing: The living environment and feeding conditions of each group of animals were in the conformity with those of each group; (5) blindly feeding: The blind method was adopt for the breeder; (6) Random outcome assessment: Evaluate the outcomes stochastically on the premise of random selection of animals; (7) Result evaluator blindly: The blind method adopted by the outcome evaluator; (8) Outcome data completely: All data of animals were included in the final analysis; (9) No selective outcome reporting: No report bias; and (10) No other sources of bias: There were no other factors that contributed to the risk of high bias.

Statistical analysis

The Revman 5.3 software was used to analyze all data, the cerebral infarction volume was considered as continuous data, and the standard mean difference with random effects model were used to assess the combined effect sizes.

RESULTS

Study inclusion

A total of 5149 relevant literatures were retrieved from six databases, in them, there were 4630 duplicates and irrelevant were excluded, resulting in 519 literatures. After reading the titles and abstracts of the enrollment articles, 449 were rejected due to review comments, reviews, case reports, clinical trials and editorials literatures. By reading the full text of the remaining 70 articles, 49 articles were eliminated as the animal model was not established by the MCAO method and the intervention drug was not NBP monotherapy; there was no control group and the infarct volume calculation formula did not meet the inclusion criteria. Ultimately, 21 eligible articles were identified^[8,16-35] (Figure 1).

Study characteristics

A total of 21 articles were collected, and among which, 5^[24,25,32,33,35] were published in Chinese and the remaining were in English. A total of 314 animals were included in 21 studies to investigate the effect of NBP on the volume of cerebral infarction in the experimental ischemic stroke model. A total of 314 animals, including 159 in the experimental group and 155 in the control group were involved in 21 studies to investigate the effect of NBP on the volume of cerebral infarction in the experimental ischemic stroke model. Moreover, in 21 articles, there were 15 studies were performed on SD rats (15/21, 71.4%), 3^[25,29,35] on Wistar rats (3/21, 14.3%), one^[22] on C57BL6/J mice (1/21, 4.8%), one^[16] on CD1 mice (1/21, 4.8%), one^[31] on 129S2/Sv mice (1/21, 4.7%); meanwhile, twenty studies of them were applied males (20/21, 95.2%), and both males and females (1/21, 4.8%) one were adopted in one study^[18]. As for anesthesia method, intraperitoneal injection of chloral hydrate in animals was used in the study of fourteen(14/21, 66.7%), injection of sodium pentobarbital in the abdominal cavity was adopted in one^[19] study (1/21, 4.8%), ketamine and xylazine




Figure 1 Literature inclusion flow chart. NBP: DI-3-n-butylphthalide; MCAO: Middle cerebral artery occlusion.

injection into the peritonealcavity in anesthesia of experimental animals were employed in one^[29] study (1/21, 4.7%), isoflurane inhalation anesthesia was accepted in the study of one^[22] (1/21, 4.8%), and only one study^[34] was adopted both atropine sulfate to reduce airway secretions, and inhalation anesthesia with isoflurane (1/21, 4.7%), in addition, three studies^[17,18,33] that were not mentioned the anesthesia methods (3/21, 14.3%). Meanwhile, the animal models used in the fifteen studies were transient MCAO (tMCAO) (15/21, 71.4%), and a permanent MCAO (pMCAO) were proceeded in six studies (6/21, 28.6%)^[16,25,29,33,35]. To detect infarction volume, there were 19 and 2^[8,22] studies adopting the 2,3,5-triphenyltetrazolium chloride and cresyl violet as the staining agents respectively (Table 1).

Study quality

Of the 21 studies, five studies got 7 points, four studies got 6 points, eight studies got 5 points, two studies got 4 points, and two studies got 3 points. None of the studies described blind feeding and random outcome assessment; the result evaluator blindness was described only in two studies^[8,32]; all studies described the data of baseline characteristics; two studies^[18,29] have found other sources of bias; no incomplete outcome data, and no selective outcome reporting were described in 11 and 17 studies, respectively (Table 2).

Effectiveness

The data of Meta-analysis of the 21 studies had suggested that NBP reduced the cerebral infarction volume of MCAO model animals compared to the control group significantly [SMD: -3.97, 95%CI: -4.71 to -3.23, $P < 0.01$; heterogeneity: $\chi^2 = 59.09$, $df = 20$ ($P < 0.01$); $I^2 = 66\%$] (Figure 2). Moreover, the data of meta-analysis of fifteen studies adopting the tMCAO model also had verified that NBP reduced infarct volume significantly [SMD: -3.67, 95%CI: -4.52 to -2.82, $P < 0.01$; heterogeneity: $\chi^2 = 42.34$, $df = 14$ ($P < 0.01$); $I^2 = 67\%$] (Figure 3A). The same is true of studies using the pMCAO model [SMD: -4.70, 95%CI: -5.92 to -3.47, $P < 0.01$; heterogeneity: $\chi^2 = 9.26$, $df = 5$ ($P = 0.10$); $I^2 = 46\%$] (Figure 3B). To analyzed the effects of the NBP on the volume of cerebral infarction with pre- or post-administrated NBP in proceeding the MCAO model, the data had showed that both the pre-administration [SMD: -3.93, 95%CI: -5.51 to -2.36, $P < 0.01$; heterogeneity: $\chi^2 = 25.58$, $df = 6$ ($P < 0.01$); $I^2 = 77\%$] (Figure 4A) and the post-administration [SMD: -3.62, 95%CI: -4.32 to -2.92, $P < 0.01$; heterogeneity: $\chi^2 = 17.92$, $df = 11$ ($P = 0.08$); $I^2 = 39\%$] (Figure 4B) all reduced the infarct volume of the model animals. A funnel plot was adopted to evaluate publication bias and a slight bias was found (Figure 5A).

DISCUSSION

Table 1 Characteristics of the included studies

Study (yr)	Species / Age, Sex / Weight, Number (Control group / Experimental group)	Anesthetic	Model	Intervention dose administration method time point / duration	Measurement of infarction volume	Outcome index	P-values
Qin <i>et al</i> ^[6] , 2018	SD rats/8 weeks	5 % chloral hydrate	tMCAO 2 h	90 mg/kg, daily	Cresyl violet	1 Infarction volume	$P < 0.05$
	Male/250-300 g	400 mg/kg	Reperfusion 7 d	Gavage	Image J	2 Ameliorate body weight loss	$P < 0.05$
	6/6	Intraperitoneally		Postoperative / 7 d		3 Improve neurological behavior scores	$P < 0.05$
						4 Reduce brain atrophy volume	$P < 0.01$
						5 Upregulate <i>PTGIS</i> , <i>PTGES</i> ; downregulate <i>TBXAS 1</i>	$P < 0.05$
						6 Prevent <i>REN</i> , <i>AGT</i> , <i>ACE 1</i> , <i>AGTR 1</i> ; upregulate <i>RoA</i>	$P < 0.05$
						7 Increase the diameter of middle cerebral artery	$P < 0.05$
Zhao <i>et al</i> ^[16] , 2018	CD 1 mice / 10-12 wk	10 % chloral hydrate	pMCAO 24 h	120 mg/kg	2% TTC	1 Infarction volume	$P < 0.05$
	Male/27-30 g	35 mg/g				2 Improve neurological behavior scores	$P < 0.05$
	10/10	Intraperitoneally				3 Decrease the water content of brain	$P < 0.05$
						4 Decrease the permeability of blood-brain barrier	$P < 0.05$
						5 Decrease pinocytotic vesicles of capillary endothelial cells	
						6 Downregulate <i>MMP 9</i>	$P < 0.05$
						7 Upregulate <i>Claudin 5</i> , <i>VEGF</i> , <i>GFAP</i> , <i>Nrf 2</i> and <i>HO 1</i>	$P < 0.05$
Wang <i>et al</i> ^[18] , 2018	SD rats/unknown	Unknown	tMCAO 2 h	1 mg/kg	2% TTC	1 Infarction volume	$P > 0.05$
	Male and female/250-280 g		Reperfusion 48 h	Intravenously	Image Pro Plus	2 Improve neurological behavior scores	$P > 0.05$
	8/12			postoperative/4 h and 24 h			
Yan <i>et al</i> ^[17] , 2017	SD rats/adult	Unknown	tMCAO 2 h	75 mg/kg, daily	2% TTC	1 Infarction volume	$P < 0.01$
	Male/180-220 g		Reperfusion 24 h	Gavage		2 Decrease the water content of brain	$P < 0.05$
	8/8			Preoperative/7 d		3 Decrease the permeability of blood-brain barrier	$P < 0.01$

						4 Decrease cell apoptosis	
						5 Decrease ROS,cleaved caspase-3, p-p38; increase SOD	$P < 0.01$
						6 Decrease MDA, p-JNK	$P < 0.05$
Zhang <i>et al</i> [19], 2016	SD rats/unknown	Sodium pentobarbital	tMCAO 1 h	4.5 mg/kg	TTC	1 Infarction volume	$P < 0.01$
	Male/250-320 g	50 mg/kg	Reperfusion 24 h	Intraperitoneally		2 Improve neurological behavior scores	$P < 0.001$
	8/8				Postoperative/-	3 Decrease the water content of brain	$P < 0.05$
						4 Upregulate HGF; downregulate TLR4	$P < 0.001$
Yin <i>et al</i> [20], 2016	SD rats/unknown	Chloral hydrate	tMCAO 2 h	80 mg/kg, daily	2% TTC	1 Infarction volume	$P < 0.001$
	Male/280-320 g	300 mg/kg	Reperfusion 24 h	Gavage	Image Pro Plus	2 Improve neurological behavior scores	$P < 0.05$
	6/6	Intraperitoneally			preoperative/7 d	3 Decrease the water content of brain	$P < 0.01$
						4 Decrease MDA	$P < 0.01$
						5 Increase SOD	$P < 0.05$
						6 Increase GSH-Px	$P < 0.001$
Hua <i>et al</i> [21], 2015	SD rats/57-61 days	Chloral hydrate	tMCAO 2 h	60 mg/kg	2% TTC	1 Infarction volume	$P < 0.05$
	Male/250-280 g	300 mg/kg	Reperfusion 24 h	Gavage	Image Pro Plus	2 Improve neurological behavior scores	$P > 0.05$
	6/6	Intraperitoneally			Postoperative/-	3 Decrease the water content of brain	$P < 0.01$
						4 Decrease MDA; increase GSH, SOD, Nrf 2, Trx, Bcl-2	$P < 0.01$
						5 Decrease NF- κ B p65; increase Txnip	$P < 0.05$
Lu <i>et al</i> [22], 2014	C57BL6/J/ dult	Isoflurane	tMCAO 0.75 h	10 mg/kg	Cresyl violet	1 Infarction volume	$P < 0.05$
	Male/ nknown	Initiated 3 %	Reperfusion 23 h	Intravenous	Image J	2 Improve neurological behavior scores	$P < 0.05$
	10/10	Maintained 1.5 %			Preoperative/-	3 Decrease MMP 9; increase TIMP 1	$P < 0.01$
						4 Increase SBP, p-ERK	$P < 0.01$
Wang <i>et al</i> [23], 2013	SD rats/unknown	Chloral hydrate	tMCAO 2 h	80 mg/kg, daily	TTC	1 Infarction volume	$P < 0.05$
	Male/280-320 g	300 mg/kg	Reperfusion 24 h	Gavage		2 Improve neurological behavior scores	$P > 0.05$
	6/6	Intraperitoneally			preoperative/7 d	3 Decrease the water content of brain	$P > 0.05$
Wang <i>et al</i> [24], 2013	SD rats/unknown	10 % chloral hydrate	tMCAO 2 h	80 mg/kg, daily	2% TTC	1 Infarction volume	$P < 0.05$
	Male/250 \pm 20 g (n = 30)	3 mL/kg	Reperfusion 24 h	Gavage		2 Downregulate GRP78, CHOP	$P < 0.05$

	5/5	Intraperitoneally		Preoperative / 7 d			
Pan <i>et al</i> ^[25] , 2013	Wistar rats/unknown	10 % chloral hydrate	pMCAO 24 h	0.8 g/kg, daily	2% TTC	1 Infarction volume	<i>P</i> < 0.05
	Male/200-250 g	3 mL/kg		Gavage	Biosens Digitan Image	2 Decrease the water content of brain	<i>P</i> < 0.05
	8/8	Intraperitoneally		Preoperative/14 d		3 Decrease Smac, S100B	<i>P</i> < 0.05
Zhang <i>et al</i> ^[26] , 2013	SD rats/unknown	6 % chloral hydrate	tMCAO 2 h	200 mg/kg	2% TTC	1 Infarction volume	<i>P</i> < 0.01
	Male/250 ± 20 g		Reperfusion 24 h	Intraperitoneally	Image Pro Plus	2 Improve neurological behavior scores	<i>P</i> < 0.01
	8/8	Intraperitoneally		Postoperative/-		3 Increase VEGF	<i>P</i> < 0.01
Wang <i>et al</i> ^[27] , 2012	SD rats/unknown	chloral hydrate	tMCAO 2 h	90 mg/kg, daily	2% TTC	1 Infarction volume	<i>P</i> < 0.05
	Male/250-300 g	300 mg/kg	Reperfusion 3 d	Gavage		2 Improve neurological behavior scores	<i>P</i> < 0.05
	10/10	Intraperitoneally		Postoperative/3 d		3 Decrease the water content of brain	<i>P</i> < 0.05
						4 Decrease the ratio of TXB ₂ : 6-keto-PGF _{1α}	<i>P</i> < 0.05
Wu <i>et al</i> ^[28] , 2012	SD rats/unknown	Chloral Hydrate	tMCAO 2 h	80 mg/kg, daily	2% TTC	1 Infarction volume	<i>P</i> < 0.001
	Male/250-280 g	350 mg/kg	Reperfusion 24 h	Gavage		2 Improve neurological behavior scores	<i>P</i> < 0.001
	6/6	Intraperitoneally		Preoperative/7 d		3 Decrease the water content of brain	<i>P</i> > 0.05
						4 Decrease MDA; increase SOD	<i>P</i> < 0.001
Zhang <i>et al</i> ^[29] , 2012	Wistar Kyoto rats/3 mo	Ketamine, xylazine	pMCAO 7 d	80 mg/kg, daily	2% TTC	1 Infarction volume	<i>P</i> < 0.01
	Male/unknown	75 mg/kg, 10 mg/kg		Gavage	Image Pro Plus		
	6/6	Intraperitoneally		Postoperative/7 d			
Zhao <i>et al</i> ^[30] , 2012	SD rats/unknown	Chloral hydrate	tMCAO 2 h	50 mg/kg, daily	2% TTC	1 Infarction volume	<i>P</i> < 0.05
	Male/250-300 g	300 mg/kg	Reperfusion 3 d	Gavage		2 Improve neurological behavior scores	<i>P</i> < 0.05
	6/6	Intraperitoneally		Postoperative / 3 d			
Li <i>et al</i> ^[31] , 2010	129S2/Sv/adult	4 % chloral hydrate	pMCAO 24 h	100 mg/kg	2% TTC	1 Infarction volume	<i>P</i> < 0.05
	Male/20-25 g			Intraperitoneally		2 Decrease cleaved-caspase 3; caspase 9, p-JNK; p-p38	<i>P</i> < 0.05
	10/10	Intraperitoneally		Postoperative 1 h/-		3 Reduce mitochondrial release of cytochrome c and AIF	<i>P</i> < 0.05
Cao <i>et al</i> ^[32] , 2009	SD rats/3-4 mo	10 % chloral hydrate	tMCAO 2 h	25 mg/kg, twice a day	TTC	1 Infarction volume	<i>P</i> < 0.01
	Male/280-350 g		Reperfusion 3 d	Gavage	Image Pro Plus	2 Improve neurological behavior scores	<i>P</i> < 0.05
	5/5	Intraperitoneally		Postoperative/3 d		3 Upregulate VEGF, bFGF	<i>P</i> < 0.05
Li <i>et al</i> ^[33] , 2008	SD rats/3-4 mo	Unknown	pMCAO 3 d	25 mg/kg, twice a day	TTC	1 Infarction volume	<i>P</i> < 0.05

Table 2 Risk of bias of the included studies

Study (yr)	A	B	C	D	E	F	G	H	I	J	Score
Qin <i>et al</i> ^[6] , 2018	√	√	√				√	√	√	√	7
Zhao <i>et al</i> ^[16] , 2018	√	√	√						√	√	5
Wang <i>et al</i> ^[18] , 2018	√		√	√				√	√		5
Yan <i>et al</i> ^[17] , 2017	√			√					√	√	4
Zhang <i>et al</i> ^[19] , 2016	√			√					√	√	4
Zhao <i>et al</i> ^[16] , 2018	√	√	√						√	√	5
Yin <i>et al</i> ^[20] , 2016	√	√	√					√	√	√	6
Hua <i>et al</i> ^[21] , 2015	√	√	√	√				√	√	√	7
Lu <i>et al</i> ^[22] , 2014	√	√	√	√				√	√	√	7
Wang <i>et al</i> ^[23] , 2013	√	√	√						√	√	5
Wang <i>et al</i> ^[24] , 2013	√	√	√					√		√	5
Pan <i>et al</i> ^[25] , 2013	√	√	√					√		√	5
Zhang <i>et al</i> ^[26] , 2013	√	√	√						√	√	5
Wang <i>et al</i> ^[27] , 2012	√	√	√						√	√	5
Wu <i>et al</i> ^[28] , 2012	√	√	√						√	√	5
Zhang <i>et al</i> ^[29] , 2012	√	√	√	√				√	√		6
Zhao <i>et al</i> ^[30] , 2012	√	√	√	√				√	√	√	7
Li <i>et al</i> ^[31] , 2010	√								√	√	3
Cao <i>et al</i> ^[32] , 2009	√	√	√	√			√	√		√	7
Li <i>et al</i> ^[33] , 2008	√	√	√	√				√		√	6
Zhang <i>et al</i> ^[34] , 2006	√	√	√	√					√	√	6
Lin <i>et al</i> ^[35] , 1996	√								√	√	3

A: Baseline characteristics; B: Allocation concealment; C: Sequence generation; D: Random housing; E: Blind feeding; F: Random outcome assessment; G: Result evaluator blind; H: No incomplete outcome data; I: No selective outcome reporting; J: No other sources of bias.

Smac in ischemic brain tissue^[25]; reduce mitochondrial release of cytochrome C and AIF^[31]; and (7) Anti-apoptosis: Reduce the expression of cleaved caspase-3, p-p38 and p-JNK in ischemic brain tissue^[17,31]; increase the expression of HGF and p-ERK in ischemic brain tissue^[19,22]; decrease the expression of GRP78 and CHOP in ischemic brain tissue, and inhibit endoplasmic reticulum stress-induced apoptosis^[24].

Implications

Animal experiments are an important link between basic research and clinical experiments. The results have reference value for the next step in designing and implementing clinical research. Compared with clinical research, the principles of randomization and blindness are theoretically easier to be implemented in animal experiments. Animal research is important for comprehending disease mechanisms, and high-quality preclinical research is also critical for translational medicine^[43,44]. Therefore, to obtain more accurate and less biased experimental data, designing animal programs should follow the guidelines all the time^[15,45], calculate sample size in the beginning, apply applicable animals, use appropriate anesthetic drugs, adopt random feeding, and blind models during the experiment, and employ random outcome measurements at the time of evaluation.

Similar to artemisinin, NBP is also a plant-derived drug approved for the treatment of acute ischemic stroke in China. We envision that NBP promote to treat more patients in the world, like artemisinin, and it requires a large number of randomized, double-blind, and multi-center clinical trials in terms of safety and efficacy.

In conclusion, we conducted the first preclinical systematic review and meta-analysis of the effects of NBP on experimental ischemic stroke, and found that NBP was effective in experimental ischemic stroke.





Figure 2 The forest plot: Effects of dl-3-n-butylphthalide for decreasing the cerebral infarction volume compared with control group.

A



B




Figure 3 The forest plot: Effects of dl-3-n-butylphthalide for decreasing the cerebral infarction volume compared with control group in transient (A) and permanent (B) middle cerebral artery occlusion model, respectively.




Figure 4 The forest plot: Effects of dl-3-n-butylphthalide for decreasing the cerebral infarction volume compared with control group in pre (A) and post-administration (B) model, respectively.




Figure 5 The funnel plot evaluation publication bias and underlying mechanism of dl-3-n-butylphthalide in neuroprotection. A: The funnel plot evaluation publication bias for the dl-3-n-butylphthalide on infarction volume; B: The underlying mechanism of dl-3-n-butylphthalide in neuroprotection.

ARTICLE HIGHLIGHTS

Research background

Ischemic stroke is a frequently-occurring disease in the elderly and characterized by high morbidity and mortality. DI-3-n-butylphthalide (NBP), a synthetic compound based on natural celery seeds, has potential therapeutic effects on cerebral ischemia, brain trauma, memory impairment, and epilepsy. The systematic review of animal research is of great significance in drug development.

Research motivation

There are many studies on the therapeutic effects of NBP in the middle cerebral artery occlusion model, and there is controversy about whether NBP reduces the volume of cerebral infarction.

Research objectives

To evaluate the effect of NBP on infarct volume in experimental ischemic stroke.

Research methods

We searched Chinese and English databases to screen NBP-related literature. Data such as cerebral infarction volume and potential therapeutic mechanisms were extracted. The risk of bias tool of the Systematic Review Centre for Laboratory animal Experimentation's was applied to assess the methodological quality of the included studies. Data analysis was performed by Revman 5.3 software.

Research results

The data of meta-analysis of the 21 studies had suggested that NBP reduced the cerebral infarction volume of middle cerebral artery occlusion (MCAO) model animals compared to the control group significantly. Moreover, the data of meta-analysis of fifteen studies adopting the tMCAO model also had verified that NBP reduced infarct volume significantly. The same is true of studies using the pMCAO model. To analyze the effects of the NBP on the volume of cerebral infarction with pre- or post-administrated NBP in proceeding the MCAO model, the data had showed that both the pre-administration and the post-administration all reduced the infarct volume of the model animals.

Research conclusions

NBP was effective in experimental ischemic stroke.

Research perspectives

Animal experiments are an important link between basic research and clinical experiments. The results have reference value for the next step in designing and implementing clinical research. Compared with clinical research, the principles of randomization and blindness are theoretically easier to be implemented in animal experiments. Animal research is important for comprehending disease mechanisms, and high-quality preclinical research is also critical for translational medicine. Therefore, to obtain more accurate and less biased experimental data, designing animal programs should follow the guidelines all the time, calculate sample size in the beginning, apply applicable animals, use appropriate anesthetic drugs, adopt random feeding, and blind models during the experiment, and employ random outcome measurements at the time of evaluation.

REFERENCES

- 1 Feigin VL, Norrving B, Mensah GA. Global Burden of Stroke. *Circ Res* 2017; **120**: 439-448 [PMID: 28154096 DOI: 10.1161/CIRCRESAHA.116.308413]
- 2 Writing Group Members. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. *Circulation* 2016; **133**: e38-360 [PMID: 26673558 DOI: 10.1161/CIR.0000000000000350]
- 3 de Ridder IR, Fransen PS, Beumer D, Berkhemer OA, van den Berg LA, Wermer MJ, Lingsma H, van Zwam WH, Roos YB, van Oostenbrugge RJ, Majoie CB, van der Lugt A, Dippel DW. Is Intra-Arterial Treatment for Acute Ischemic Stroke Less Effective in Women than in Men? *Interv Neurol* 2016; **5**: 174-178 [PMID: 27781046 DOI: 10.1159/000447331]
- 4 Chen HS, Qi SH, Shen JG. One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke. *Curr Neuropharmacol* 2017; **15**: 134-156 [PMID: 27334020]
- 5 Jickling GC, Sharp FR. Improving the translation of animal ischemic stroke studies to humans. *Metab Brain Dis* 2015; **30**: 461-467 [PMID: 24526567 DOI: 10.1007/s11011-014-9499-2]
- 6 Wang S, Ma F, Huang L, Zhang Y, Peng Y, Xing C, Feng Y, Wang X, Peng Y. DL-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke. *CNS Neurol Disord Drug Targets* 2018; **17**: 338-347 [PMID: 29895257 DOI: 10.2174/1871527317666180612125843]
- 7 Zhao Y, Li J, Zhang P, Chen C, Li S. Protective effects of dl-3n-butylphthalide against diffuse brain injury. *Neural Regen Res* 2013; **8**: 2615-2624 [PMID: 25206572 DOI: 10.3969/j.issn.1673-5374.2013.28.003]
- 8 Qin C, Zhou P, Wang L, Mamtilahun M, Li W, Zhang Z, Yang GY, Wang Y. DL-3-N-butylphthalide attenuates ischemic reperfusion injury by improving the function of cerebral artery and circulation. *J Cereb Blood Flow Metab* 2018; 271678X18776833 [PMID: 29762050 DOI: 10.1177/0271678X18776833]
- 9 Zhao Y, Lee JH, Chen D, Gu X, Caslin A, Li J, Yu SP, Wei L. DL-3-n-butylphthalide induced neuroprotection, regenerative repair, functional recovery and psychological benefits following traumatic brain injury in mice. *Neurochem Int* 2017; **111**: 82-92 [PMID: 28359729 DOI: 10.1016/j.neuint.2017.03.017]
- 10 Xiong Z, Lu W, Zhu L, Zeng L, Shi C, Jing Z, Xiang Y, Li W, Tsang CK, Ruan Y, Huang L. DL-3-n-Butylphthalide Treatment Enhances Hemodynamics and Ameliorates Memory Deficits in Rats with Chronic Cerebral Hypoperfusion. *Front Aging Neurosci* 2017; **9**: 238 [PMID: 28798681 DOI: 10.3389/fnagi.2017.00238]
- 11 Liu RZ, Fan CX, Zhang ZL, Zhao X, Sun Y, Liu HH, Nie ZX, Pu XP. Effects of DL-3-n-butylphthalide on Cerebral Ischemia Infarction in Rat Model by Mass Spectrometry Imaging. *Int J Mol Sci* 2017; **18**: E2451 [PMID: 29165327 DOI: 10.3390/ijms18112451]
- 12 Feng L, Sharma A, Niu F, Huang Y, Lafuente JV, Muresanu DF, Ozkizilcik A, Tian ZR, Sharma HS.

- TiO₂-Nanowired Delivery of DL-3-n-butylphthalide (DL-NBP) Attenuates Blood-Brain Barrier Disruption, Brain Edema Formation, and Neuronal Damages Following Concussive Head Injury. *Mol Neurobiol* 2018; **55**: 350-358 [PMID: 28856586 DOI: 10.1007/s12035-017-0746-5]
- 13 **de Vries RB**, Wever KE, Avey MT, Stephens ML, Sena ES, Leenaars M. The usefulness of systematic reviews of animal experiments for the design of preclinical and clinical studies. *ILAR J* 2014; **55**: 427-437 [PMID: 25541545 DOI: 10.1093/ilar/ilu043]
- 14 **Stewart LA**, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA* 2015; **313**: 1657-1665 [PMID: 25919529 DOI: 10.1001/jama.2015.3656]
- 15 **Hooijmans CR**, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. *BMC Med Res Methodol* 2014; **14**: 43 [PMID: 24667063 DOI: 10.1186/1471-2288-14-43]
- 16 **Zhao YJ**, Nai Y, Ma QS, Song DJ, Ma YB, Zhang LH, Mi LX. DL-3-n-butylphthalide protects the blood brain barrier of cerebral infarction by activating the Nrf-2/HO-1 signaling pathway in mice. *Eur Rev Med Pharmacol Sci* 2018; **22**: 2109-2118 [PMID: 29687870 DOI: 10.26355/eurrev_201804_14744]
- 17 **Yan RY**, Wang SJ, Yao GT, Liu ZG, Xiao N. The protective effect and its mechanism of 3-n-butylphthalide pretreatment on cerebral ischemia reperfusion injury in rats. *Eur Rev Med Pharmacol Sci* 2017; **21**: 5275-5282 [PMID: 29228445 DOI: 10.26355/eurrev_201711_13852]
- 18 **Wang Y**, Huang Y, Xu Y, Ruan W, Wang H, Zhang Y, Saavedra JM, Zhang L, Huang Z, Pang T. A Dual AMPK/Nrf2 Activator Reduces Brain Inflammation After Stroke by Enhancing Microglia M2 Polarization. *Antioxid Redox Signal* 2018; **28**: 141-163 [PMID: 28747068 DOI: 10.1089/ars.2017.7003]
- 19 **Zhang P**, Guo ZF, Xu YM, Li YS, Song JG. N-Butylphthalide (NBP) ameliorated cerebral ischemia reperfusion-induced brain injury via HGF-regulated TLR4/NF- κ B signaling pathway. *Biomed Pharmacother* 2016; **83**: 658-666 [PMID: 27468961 DOI: 10.1016/j.biopha.2016.07.040]
- 20 **Yin W**, Lan L, Huang Z, Ji J, Fang J, Wang X, Ji H, Peng S, Xu J, Zhang Y. Discovery of a ring-opened derivative of 3-n-butylphthalide bearing NO/H₂S-donating moieties as a potential anti-ischemic stroke agent. *Eur J Med Chem* 2016; **115**: 369-380 [PMID: 27031213 DOI: 10.1016/j.ejmech.2016.03.044]
- 21 **Hua K**, Sheng X, Li TT, Wang LN, Zhang YH, Huang ZJ, Ji H. The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats. *Acta Pharmacol Sin* 2015; **36**: 917-927 [PMID: 26073328 DOI: 10.1038/aps.2015.31]
- 22 **Lu YM**, Huang JY, Wang H, Lou XF, Liao MH, Hong LJ, Tao RR, Ahmed MM, Shan CL, Wang XL, Fukunaga K, Du YZ, Han F. Targeted therapy of brain ischaemia using Fas ligand antibody conjugated PEG-lipid nanoparticles. *Biomaterials* 2014; **35**: 530-537 [PMID: 24120040 DOI: 10.1016/j.biomaterials.2013.09.093]
- 23 **Wang X**, Wang L, Li T, Huang Z, Lai Y, Ji H, Wan X, Xu J, Tian J, Zhang Y. Novel hybrids of optically active ring-opened 3-n-butylphthalide derivative and isosorbide as potential anti-ischemic stroke agents. *J Med Chem* 2013; **56**: 3078-3089 [PMID: 23509954 DOI: 10.1021/jm4001693]
- 24 **Wang W**, Kong W, Chen M, Zheng X, Zhao S, Kong X. Effects of 3-n-butylphthalide pretreatment on endoplasmic reticulum stress in rats with cerebral ischemia reperfusion. *Linchuang Shenjingbingxue Zazhi* 2013; **26**: 122-124
- 25 **Pan J**, Chen X, Li Q, Song D. Brain protective effect of butylphthalide preconditioning in rat with cerebral ischemics. *Linchuang Shenjingbingxue Zazhi* 2013; **26**: 44-46
- 26 **Zhang PL**, Lu HT, Zhao JG, Li MH. Protective effect of dl-3n-butylphthalide preconditioning on focal cerebral ischaemia-reperfusion injury in rats. *Acta Neuropsychiatr* 2013; **25**: 12-17 [PMID: 26953069 DOI: 10.1111/j.1601-5215.2012.00649.x]
- 27 **Wang X**, Zhao Q, Wang X, Li T, Lai Y, Peng S, Ji H, Xu J, Zhang Y. Studies on the enantiomers of ZJM-289: synthesis and biological evaluation of antiplatelet, antithrombotic and neuroprotective activities. *Org Biomol Chem* 2012; **10**: 9030-9040 [PMID: 23076046 DOI: 10.1039/c2ob26511g]
- 28 **Wu J**, Ling J, Wang X, Li T, Liu J, Lai Y, Ji H, Peng S, Tian J, Zhang Y. Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one. *J Med Chem* 2012; **55**: 7173-7181 [PMID: 22827516 DOI: 10.1021/jm300681r]
- 29 **Zhang L**, Yu WH, Wang YX, Wang C, Zhao F, Qi W, Chan WM, Huang Y, Wai MS, Dong J, Yew DT. DL-3-n-Butylphthalide, an anti-oxidant agent, prevents neurological deficits and cerebral injury following stroke per functional analysis, magnetic resonance imaging and histological assessment. *Curr Neurovasc Res* 2012; **9**: 167-175 [PMID: 22621233]
- 30 **Zhao Q**, Zhang C, Wang X, Chen L, Ji H, Zhang Y. (S)-ZJM-289, a nitric oxide-releasing derivative of 3-n-butylphthalide, protects against ischemic neuronal injury by attenuating mitochondrial dysfunction and associated cell death. *Neurochem Int* 2012; **60**: 134-144 [PMID: 22142531 DOI: 10.1016/j.neuint.2011.11.013]
- 31 **Li J**, Li Y, Ogle M, Zhou X, Song M, Yu SP, Wei L. DL-3-n-butylphthalide prevents neuronal cell death after focal cerebral ischemia in mice via the JNK pathway. *Brain Res* 2010; **1359**: 216-226 [PMID: 20800583 DOI: 10.1016/j.brainres.2010.05.044]
- 32 **Cao W**, De Ji Qu Z, Li Q, He L, Zhou D. Effects of dl23n2butylphthalide on the Expression of VEGF and bFGF in Transient Middle Cerebral Artery Occlusion Rats. *Sichuan Daxue Xuebao (Yixue Ban)* 2009; **40**: 403-407
- 33 **Li Q**, Kong S, De Ji Qu Z, He L, Zhou D. Effects of dl-3-n-butylphthalide on Expression of VEGF and bFGF in Rat Brain with Permanent Focal Cerebral Ischemia. *Sichuan Daxue Xuebao (Yixue Ban)* 2008; **39**: 84-88
- 34 **Zhang Y**, Wang L, Li J, Wang XL. 2-(1-Hydroxypentyl)-benzoate increases cerebral blood flow and reduces infarct volume in rats model of transient focal cerebral ischemia. *J Pharmacol Exp Ther* 2006; **317**: 973-979 [PMID: 16527903 DOI: 10.1124/jpet.105.098517]
- 35 **Lin JF**, Feng YP. [Effect of dl-3-n-butylphthalide on delayed neuronal damage after focal cerebral ischemia and intrasynaptosomes calcium in rats]. *Yao Xue Xue Bao* 1996; **31**: 166-170 [PMID: 9206264]
- 36 **Schumacher K**, Kornej J, Shantsila E, Lip GYH. Heart Failure and Stroke. *Curr Heart Fail Rep* 2018; **15**: 287-296 [PMID: 30062623 DOI: 10.1007/s11897-018-0405-9]
- 37 **Fan YL**, Zhan R, Dong YF, Huang L, Ji XX, Lu P, Liu J, Li P, Cheng XS. Significant interaction of hypertension and homocysteine on neurological severity in first-ever ischemic stroke patients. *J Am Soc Hypertens* 2018; **12**: 534-541 [PMID: 29678422 DOI: 10.1016/j.jash.2018.03.011]
- 38 **Dandapat S**, Robinson JG. Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. *Curr Neurol Neurosci Rep* 2016; **16**: 24

- [PMID: 26838351 DOI: 10.1007/s11910-016-0621-1]
- 39 **Hu WS**, Lin CL. Use of the progression of adapted Diabetes Complications Severity Index to predict acute coronary syndrome, ischemic stroke, and mortality in Asian patients with type 2 diabetes mellitus: A nationwide cohort investigation. *Clin Cardiol* 2018; **41**: 1038-1043 [PMID: 29896758 DOI: 10.1002/clc.22991]
- 40 **Céspedes Rubio ÁE**, Pérez-Alvarez MJ, Lapuente Chala C, Wandosell F. Sex steroid hormones as neuroprotective elements in ischemia models. *J Endocrinol* 2018; **237**: R65-R81 [PMID: 29654072 DOI: 10.1530/JOE-18-0129]
- 41 **Zeng ZW**, Zhang YN, Lin WX, Zhang WQ, Luo R. A meta-analysis of pharmacological neuroprotection in noncardiac surgery: focus on statins, lidocaine, ketamine, and magnesium sulfate. *Eur Rev Med Pharmacol Sci* 2018; **22**: 1798-1811 [PMID: 29630129 DOI: 10.26355/eurrev_201803_14599]
- 42 **Bell JD**. In Vogue: Ketamine for Neuroprotection in Acute Neurologic Injury. *Anesth Analg* 2017; **124**: 1237-1243 [PMID: 28079589 DOI: 10.1213/ANE.0000000000001856]
- 43 **Fluri F**, Schuhmann MK, Kleinschnitz C. Animal models of ischemic stroke and their application in clinical research. *Drug Des Devel Ther* 2015; **9**: 3445-3454 [PMID: 26170628 DOI: 10.2147/DDDT.S56071]
- 44 **Hackam DG**, Redelmeier DA. Translation of research evidence from animals to humans. *JAMA* 2006; **296**: 1731-1732 [PMID: 17032985 DOI: 10.1001/jama.296.14.1731]
- 45 **Kilkenny C**, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *Osteoarthritis Cartilage* 2012; **20**: 256-260 [PMID: 22424462 DOI: 10.1016/j.joca.2012.02.010]



Published By Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

